Literature DB >> 28666913

Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort.

Yu Nakagawa1, Hikaru Sasaki2, Kentaro Ohara3, Taketo Ezaki1, Masahiro Toda1, Takayuki Ohira1, Takeshi Kawase1, Kazunari Yoshida1.   

Abstract

OBJECTIVE: The purpose of this study was to clarify the clinical and molecular characteristics associated with long-term survival in patients with glioblastoma.
METHODS: We analyzed the characteristics of 96 glioblastoma patients. Long-term survivors (LTSs) were classified into moderate LTSs (mLTSs), who survived >3 years, and LTSs, who survived >5 years, and compared with short-term survivors (STSs). Clinical and molecular factors were investigated.
RESULTS: Younger age, better recursive partitioning analysis class, lack of subventricular zone (SVZ) involvement, promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene, and loss of 19q were associated with mLTSs as compared with STSs. After adjustment for these factors, younger age and MGMT methylation remained independently associated with mLTSs. Younger age, better recursive partitioning analysis class, lack of SVZ involvement, and loss of 19q were associated with LTSs as compared with STSs. After adjustment, younger age and better preoperative Karnofsky performance scale (KPS) score remained independently associated with LTSs. Kaplan-Meier analyses revealed that younger age (<50 years), better preoperative KPS score (≥70), lack of SVZ involvement, and loss of 19q were associated with longer overall survival. In the multivariate analysis, only age was significantly associated with overall survival.
CONCLUSIONS: Younger age and better preoperative KPS score were the characteristics associated with LTSs as compared with STSs. MGMT promoter methylation was associated with mLTSs, but not with LTSs. In addition, lack of SVZ involvement and loss of 19q might be prognostic for longer survival.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Age; Glioblastoma; Long-term survival; Loss of 19q; MGMT; Subventricular zone involvement

Mesh:

Substances:

Year:  2017        PMID: 28666913     DOI: 10.1016/j.wneu.2017.06.126

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  9 in total

1.  Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma.

Authors:  Özlem Yersal; Eylem Odabaşi; Özge Özdemir; Yasemin Kemal
Journal:  Mol Clin Oncol       Date:  2018-08-09

Review 2.  Clinical and immunological correlates of long term survival in glioblastoma.

Authors:  Bartosz Czapski; Szymon Baluszek; Christel Herold-Mende; Bozena Kaminska
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

Review 3.  MinION rapid sequencing: Review of potential applications in neurosurgery.

Authors:  Arpan Patel; Evgenii Belykh; Eric J Miller; Laeth L George; Nikolay L Martirosyan; Vadim A Byvaltsev; Mark C Preul
Journal:  Surg Neurol Int       Date:  2018-08-10

4.  Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.

Authors:  Michael T C Poon; Cathie L M Sudlow; Jonine D Figueroa; Paul M Brennan
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

5.  Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma.

Authors:  Taeyoung Hwang; Dimitrios Mathios; Kerrie L McDonald; Irene Daris; Sung-Hye Park; Peter C Burger; Sojin Kim; Yun-Sik Dho; Hruban Carolyn; Chetan Bettegowda; Joo Heon Shin; Michael Lim; Chul-Kee Park
Journal:  Acta Neuropathol Commun       Date:  2019-06-03       Impact factor: 7.578

6.  Adverse prognosis of glioblastoma contacting the subventricular zone: Biological correlates.

Authors:  Sharon Berendsen; Emma van Bodegraven; Tatjana Seute; Wim G M Spliet; Marjolein Geurts; Jeroen Hendrikse; Laurent Schoysman; Willemijn B Huiszoon; Meri Varkila; Soufyan Rouss; Erica H Bell; Jérôme Kroonen; Arnab Chakravarti; Vincent Bours; Tom J Snijders; Pierre A Robe
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

7.  Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma.

Authors:  Arshad A Pandith; Iqbal Qasim; Shahid M Baba; Aabid Koul; Wani Zahoor; Dil Afroze; Adil Lateef; Usma Manzoor; Ina A Bhat; Dheera Sanadhya; Abdul R Bhat; Altaf U Ramzan; Fozia Mohammad; Iqra Anwar
Journal:  Future Sci OA       Date:  2020-12-09

8.  Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.

Authors:  Haihui Jiang; Kefu Yu; Yong Cui; Xiaohui Ren; Mingxiao Li; Guobin Zhang; Chuanwei Yang; Xuzhe Zhao; Qinghui Zhu; Song Lin
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

9.  The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.

Authors:  Huy Gia Vuong; Thu Quynh Nguyen; Tam N M Ngo; Hoang Cong Nguyen; Kar-Ming Fung; Ian F Dunn
Journal:  BMC Cancer       Date:  2020-09-21       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.